SecBot SecBot
Institutional Cluster

ARDX

ARDELYX, INC.
NEUTRAL
Impact 3/10
Horizonweeks Processed12d 4h ago
Institutional cluster: 6 buyers, 4 sellers (mixed)
Actionable Insight • Neutral

The mixed 13F cluster shows modest net buying from asset managers but lacks insider corroboration. With Q3 earnings already released and guidance reiterated, watch for any insider Form 4 filings or a material change in the ACCEL trial timeline that could shift institutional conviction.

DirectionNeutral
Confidencemedium
Horizonweeks

tenapanor

● Neutral Named in this fund cluster
Impact
Phase
Approved (IBS-C and hyperphosphatemia); Phase 3 for CIC
Time to market
Already on the market for IBS-C (since 2021 launch) and hyperphosphatemia (since 2023 launch). CIC label expansion would be the next milestone, with data expected H2 2027 and potential FDA filing in 2028.
Next catalyst
None dated

What to watchTenapanor is a mature commercial asset with no near-term binary catalyst. Watch the Q4 2026 earnings (expected early 2027) for whether IBSRELA revenue growth stabilizes or continues decelerating. The Phase 3 ACCEL CIC readout in H2 2027 is the next major value-inflection point, but it is over 12 months away. In the meantime, payor access dynamics and prescription trends will drive the stock more than any single event.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$2.99
T+0 close · Nov 5, 2026 · via day close
Latest settled
+4.35%
T+5 · $3.12
Vs SPY
+1.06%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $2.99entry
  2. T+1 · 11d ago −3.68%α −3.99% · $2.88
  3. T+5 · 5d ago +4.35%α +1.06% · $3.12
  4. T+8 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Institutional 13F filings for Q3 2026 show a mixed cluster in ARDX: 6 buyers added $4.4M in net new holdings (led by Citigroup and Mackenzie Financial), while 4 sellers trimmed $977K. The buying appears to align with Q3 earnings reported two days ago (revenue up 19% YoY, narrowed net loss), but the cluster is dominated by asset managers rather than activist or high-conviction funds, and the 45-day reporting lag means positions may have changed since quarter-end.

Key Financial Metrics

Direction
mixed
Buy Value
$9.3M
Net Flow
$3.4M

Institutional Positions

Net institutional flow: $3.4M

▲ Buyers (6)

InstitutionActionChangePosition ValueValue Δ
CitigroupDOUBLED+338.3%$4.7M$3.1M
Mackenzie FinancialADD+88.5%$3.1M$638.0K
Creative PlanningDOUBLED+410.9%$782.0K$554.0K

▼ Sellers (4)

InstitutionActionChangePrev ValueValue Δ
Simplex TradingTRIM-46.7%$772.0K-$496.0K
Wealth Enhancement Advisory ServicesTRIM-73.4%$452.0K-$377.0K
Commonwealth Equity ServicesTRIM-34.3%$181.0K-$102.0K

Key Facts

  • 6 institutional buyers added $4.4M in net new holdings during Q3 2026
  • 4 institutional sellers trimmed $977K in aggregate
  • Largest buyer: Citigroup doubled its position to $4.7M (Δ+$3.1M)
  • Largest seller: Simplex Trading trimmed 46.7% of its position, reducing value by $496K
  • All participants are asset managers; no activist or hedge fund with a concentrated bet
  • Insider trading confluence score is low (17/100) with no open-market insider buying
  • Q3 2026 earnings (reported 2 days ago) showed 19% revenue growth and narrowed net loss

Financial Impact

6 buyers accumulated $4.4M in new positions while 4 sellers reduced holdings by $977K; net institutional inflow of approximately $3.4M

institutional ownershipfloat

Risk Factors

  • 13F data is 45+ days stale; positions may have been unwound since quarter-end
  • No insider buying to corroborate the institutional accumulation signal
  • Cluster is dominated by asset managers, not high-conviction activist or concentrated funds
  • Net buying of $3.4M is small relative to $755M market cap (0.45%)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-ARDX-2026-Q3

Track record

20 reports on ARDX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 17, 2026today SC 13G Neutral 4/10 Entry price pending
  2. Nov 5, 202612d ago Institutional Cluster Neutral 3/10 Viewing Entry $2.99 settles Feb 3
  3. Nov 3, 202614d ago 8-K Neutral 4/10 No price data
  4. Nov 3, 202614d ago Press Release Neutral 4/10 Entry $3.29 settles Feb 2
  5. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $3.39 settles Dec 30
  6. Aug 25, 202611w ago Insider Cluster Neutral 2/10 Entry $3.83 settles Nov 19
  7. Aug 25, 202611w ago Insider Cluster Neutral 2/10 Entry $3.83 settles Nov 19
  8. Aug 21, 202612w ago 144 Neutral 2/10 Entry $3.74 to $3.18 ▼ −14.97% −10.91% vs SPY
  9. Aug 21, 202612w ago 144 Neutral 2/10 Entry $3.74 to $3.18 ▼ −14.97% −10.91% vs SPY
  10. Aug 17, 202613w ago 8-K Neutral 2/10 Entry $3.92 to $3.01 ▼ −23.21% −21.17% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026